Skip to content

Study · Animal study (in vivo) · monachus schauinslandi · 1998

1 result

Use of a GnRH agonist to suppress testosterone in wild male Hawaiian monk seals (Monachus schauinslandi).

Atkinson S, Ragen TJ, Gilmartin WG, Becker BL, Johanos TC

General and comparative endocrinology1 Nov 1998Cited by 4 (Europe PMC)

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In wild male Hawaiian monk seals, triptorelin significantly reduced circulating testosterone from 1.01 to 0.21 ng/ml approximately 38 days later.

    In plain wordsIn wild male Hawaiian monk seals, circulating testosterone decreased significantly after triptorelin compared with initial levels.

    Outcome
    DecreaseCirculating testosterone
    Study

    Monachus schauinslandin = 8

    Wild adult male Hawaiian monk seals
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    7.5 mgAs given in this study (Monachus schauinslandi).

    Measurements

    Testosterone
    1.01 ng/ml
    first sample
    Testosterone
    0.21 ng/ml
    second sample approximately 38 days later

    Source sentences

    Summary
    In the treated group, the agonist induced a significant decline in mean circulating testosterone concentrations, from 1.01 ng/ml (first sample) to 0.21 ng/ml (second sample, taken approximately 38 days later).
    3 context sentences
    Summary · context
    A gonadotropin-releasing hormone (GnRH) agonist, d-Trp6-LHRH, was evaluated for its effectiveness in reducing circulating testosterone concentrations in wild Hawaiian monk seals (Monachus schauinslandi).
    Summary · context
    Twenty-eight adult male seals were randomly divided into three groups: 10 were captured and treated with 7.5 mg of the GnRH agonist, 9 were captured but did not receive the agonist, and 9 were captured near the end of the study to serve as handling controls.
    Summary · context
    From 14 to 58 days after initial capture, 8 of the treated seals and 8 of the untreated seals were recaptured and a second sample of blood was taken.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.